Imaging table offers various motorized movements
April 27th 2003The Medstone Pro-2000BT carbon fiber C-arm table allows imaging for urology,brachytherapy, surgery, and other procedures. Motorized movements include16-inch longitudinal travel, 12-inch to 16-inch vertical travel, 8-inchlateral travel, ±15-degree Trendelenberg tilt, and optional ±15-degreelateral tilt.
Antibody allows physicians to decipher PCa stages
April 27th 2003ProstaScint (In-111 capromab pendetide) from Cytogen Corp. is a radiolabeledmonoclonal antibody specific to prostate-specific membrane antigen. Theproduct aids in the staging of prostate cancer, allowing physicians to makecritical distinctions between localized and metastasized disease.
Point-of-care PSA test provides results in 15 minutes
April 27th 2003Lab-quality PSA and testosterone test results are now available on demandwith the FastPack System from Qualigen, Inc. The system includes a fullyautomated analyzer designed to perform quantitative immunoassay tests within15 minutes in physician offices and small laboratories, according to thecompany.
Bladder cancer test offers results in 30 minutes
April 27th 2003Cytogen Corp. and Matritech, Inc., offer the NMP22 BladderChek point-of-caretest for bladder cancer, which is now approved for detecting the disease.The product had been previously approved for monitoring patients who hadalready been diagnosed with bladder cancer.
Thermotherapy system is flexible in treatment site
April 27th 2003The Targis System from Urologix, designed to treat BPH symptoms, consistsof a control unit, a catheter-based microwave delivery system (MDS), a coolingbag, and a rectal thermo-sensing unit. The control unit supplies microwaveenergy and coolant and collects and processes data from other parts of thesystem.
Shorter-length catheter suits patients with smaller prostates
April 27th 2003Urologix introduces the shorter-length Targis catheter to allow morepatients to be treated with the company's Cooled ThermoTherapy treatmentfor BPH. The catheter was designed to treat the estimated 15% to 20% ofpatients who have smaller prostates, according to the company.
System uses cooled therapy to treat BPH symptoms
April 1st 2003Urologix, Inc., offers the Prostatron System, which is designed to reducethe symptoms and obstruction due to BPH by delivering a controlled doseof microwave energy to the prostate without damaging the urethra or surroundingstructures. The system delivers microwave energy to the prostate transurethrallythrough a specially designed treatment catheter that encases a tiny microwaveantenna.
Fiberscope offers navigation of renal collecting system
April 1st 2003Karl Storz Endoscopy-America, Inc., offers the new 7.5F Flex-X Uretero-Reno-Fiberscope,which offers ease of entry to the lower pole calyces and navigation of theentire renal collecting system. The product delivers larger, higher-resolutionimages for improved tissue differentiation. The single-lever control ofthe bending section provides surgeons with intuitive navigation and operationcontrol, according to the company.
Transdermal system approved for overactive bladder
April 1st 2003Watson Pharma, Inc., has received FDA approval to market oxybutynin transdermal system (Oxytrol) for the treatment of overactive bladder, with symptoms of urge urinary incontinence, urgency, and frequency. A thin patch applied to the abdomen, hip, or buttock twice weekly, it delivers 3.9 mg per day of oxybutynin consistently and continuously through the skin into the bloodstream, according to the company.
Managing chronic prostatitis: A modern approach
April 1st 2003Nearly one in 10 men who walk into the outpatient office of a urologist leave with a coded diagnosis of prostatitis. Urologists have described the traditional approach to the diagnosis and management of the chronic prostatitis syndromes as one of the most frustrating areas of urologic practice.
Treat infertile males beyond their reproductive concerns
April 1st 2003One does not have to go far on the Internet to find solicitations encouragingcouples whose infertility derives from a wide variety of causes to undergointracytoplasmic sperm injection with aspirated testicular sperm. Many ofthese advertisements hint that ICSI with aspirated sperm is an easy, "one-stop"method of conceiving a child, leading urologists to be rightly concernedthat, without adequate evaluation of the male half of the equation, thepatient's medical interests are inadequately served.
Thompson: 'It's time for a national solution'
April 1st 2003In this exclusive Urology Times interview, Health and Human Services Secretary Tommy G. Thompson addresses the medical liability insurance crisis and outlines several possible solutions. Thompson also discusses the future of managed care, his plans for restructuring Medicare, and his goals for HHS during his tenure. The interview was conducted by Michael T. McCue, editor-in-chief of Managed Healthcare Executive, a UT sister publication.